<p>Adverum 生物科技公司（NASDAQ:ADVM - 獲取免費報告）在八月份的空頭頭寸顯著增長。截至 8 月 15 日，空頭頭寸總計為 1,500,000 股，比 7 月 31 日的 1,260,000 股增長了 19.0%。該公司約有 10.7% 的股份被空頭持有。基於平均每日成交量為 329,000 股，目前的空頭頭寸比率為 4.6 天。</p>
<h2>Adverum 生物科技交易上漲 0.9%</h2>
<p>ADVM 股票週五開盤價為 6.94 美元。該公司的市值為 1.4405 億美元，市盈率為-0.68，貝塔係數為 1.07。該公司的 50 日移動平均價格為 7.33 美元，200 日移動平均價格為 10.77 美元。Adverum 生物科技的 12 個月最低價為 6.38 美元，最高價為 29.70 美元。</p>
<p>Adverum 生物科技（NASDAQ:ADVM - 獲取免費報告）於 8 月 12 日星期一發布了季度財報。這家生物技術公司報告稱，該季度每股虧損為（0.89）美元，超過了每股（1.47）美元的共識預期，增加了 0.58 美元。研究分析師預測，Adverum 生物科技今年將實現-5.5 美元的每股收益。</p>
<h2>Adverum 生物科技內部交易活動</h2>
<p>在其他 Adverum 生物科技的消息中，主要股東 Braden Michael Leonard 於 7 月 30 日星期二以每股 7.15 美元的平均價格購買了公司的 85,800 股股票。交易金額為 613,470.00 美元。交易後，該內部人士現在持有公司股票的 2,268,064 股，價值約 16,216,657.60 美元。該交易已在提交給證券交易委員會的文件中披露，可在此超鏈接中找到。公司股份的 4.20% 歸內部人士所有。</p>
<h2>機構投資者對 Adverum 生物科技的看法</h2>
<p>幾家對沖基金和其他機構投資者最近買賣了 ADVM 的股票。Picton Mahoney Asset Management 在第一季度收購了 Adverum 生物科技的股份，價值約 1,755,000 美元。Assenagon Asset Management S.A.在第二季度增加了對 Adverum 生物科技的持股，持股比例增加了 72.3%，現在擁有 617,910 股該生物技術公司的股票，價值 4,239,000 美元，較上一季度增加了 259,191 股。Avoro Capital Advisors LLC 在第一季度購買了 Adverum 生物科技的新頭寸，價值約 5,892,000 美元。Squarepoint Ops LLC 在第二季度將其對 Adverum 生物科技的持倉增加了 301.1%。Squarepoint Ops LLC 現在擁有 108,978 股該生物技術公司的股票，價值 748,000 美元，較上一季度增加了 81,808 股。最後，Marshall Wace LLP 在第二季度增加了對 Adverum 生物科技的持股比例 52.9%。Marshall Wace LLP 現在擁有 204,619 股該生物技術公司的股票，價值 1,404,000 美元，較上一季度增加了 70,768 股。48.17% 的股份目前由對沖基金和其他機構投資者持有。</p>
<h2>分析師設定新的價格目標</h2>
<p>ADVM 已成為多家研究分析師報告的主題。StockNews.com 在 8 月 15 日的報告中將 Adverum 生物科技的股票評級從 “賣出” 調升至 “持有”。HC Wainwright 重申了對 Adverum 生物科技的 “買入” 評級，並設定了 30.00 美元的價格目標。皇家銀行降低了對 Adverum 生物科技的價格目標，從 15.00 美元降至 12.00 美元，並在一份研究報告中將其股票評級定為 “行業表現”。Oppenheimer 在 6 月 25 日的研究報告中對 Adverum 生物科技進行了覆蓋。他們給出了 “表現優異” 的評級，併為該公司設定了 25.00 美元的價格目標。最後，Truist Financial 將 Adverum 生物科技的價格目標從 60.00 美元降至 40.00 美元，併為該公司設定了 “買入” 評級。兩家分析師給予該股票持有評級，五家給予買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “中等買入”，共識目標價為 28.17 美元。</p>
<p><strong>獲取我們關於 Adverum 生物科技的最新股票報告</strong></p>
<h2>關於 Adverum 生物科技（獲取免費報告）</h2>
<p>Adverum 生物科技公司是一家臨牀階段公司，開發基因療法產品候選藥物以治療眼部疾病。其主要產品候選藥物是 ixoberogene soroparvovec（ADVM-022），這是一種單次眼內注射基因療法候選藥物，用於治療患有濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的患者，目前正在進行 2 期臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五支股票勝過 Adverum 生物科技</li>
<li>公用事業股票解釋 - 如何以及為什麼投資公用事業</li>
<li>太陽能股票之戰：大全或晶科能源，哪個是你的下一個大贏家？</li>
<li>投資的不同類型股票</li>
<li>這些中國股票值得購買嗎？邁克爾·伯裏的首選股票説是</li>
<li>商業服務股票投資</li>
<li>儘管收入增長強勁，Five Below 股票面臨挑戰</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 揭示：9 月 23 日將爆發 3 美分加密貨幣？（來自 True Market Insiders）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzYz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzYz"/></p>
<h2>您現在是否應該投資 1,000 美元購買 Adverum 生物科技的股票？</h2>
<p>在考慮 Adverum 生物科技之前，您需要聽到這個。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了頂級分析師悄悄告訴客户現在應該購買的五隻股票，然後等待整個市場的關注... 而 Adverum Biotechnologies 並不在這份名單上。</p>
<p>雖然 Adverum Biotechnologies 目前在分析師中有一個 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Adverum生物科技

<p>Adverum 生物科技（NASDAQ:ADVM）在八月份經歷了短頭寸大幅增加的情況，增幅達到了 19.0%，達到了 150 萬股。目前，公司的 10.7% 股份被空頭持有，根據平均交易量為 329,000 股，以 4.6 天的交易天數來計算。該公司的市值為 5,000 萬美元，股價為 0.94 美元。分析師持有 “中等買入” 一致評級，目標價為 1.17 美元。內部人員和機構投資者的活動表明對該股票的興趣正在增加</p>

<p>Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 1,500,000 shares, a growth of 19.0% from the July 31st total of 1,260,000 shares. Approximately 10.7% of the shares of the company are sold short. Based on an average daily volume of 329,000 shares, the short-interest ratio is currently 4.6 days.</p>
<div class="lb-trans"><p>Adverum 生物科技公司（NASDAQ:ADVM - 獲取免費報告）在八月份的空頭頭寸顯著增長。截至 8 月 15 日，空頭頭寸總計為 1,500,000 股，比 7 月 31 日的 1,260,000 股增長了 19.0%。該公司約有 10.7% 的股份被空頭持有。基於平均每日成交量為 329,000 股，目前的空頭頭寸比率為 4.6 天。</p>
</div><h2>Adverum Biotechnologies Trading Up 0.9 %</h2>
<div class="lb-trans"><h2>Adverum 生物科技交易上漲 0.9%</h2>
</div><p>Shares of ADVM stock opened at $6.94 on Friday. The company has a market capitalization of $144.05 million, a price-to-earnings ratio of -0.68 and a beta of 1.07. The firm has a 50-day moving average price of $7.33 and a 200 day moving average price of $10.77. Adverum Biotechnologies has a twelve month low of $6.38 and a twelve month high of $29.70.</p>
<div class="lb-trans"><p>ADVM 股票週五開盤價為 6.94 美元。該公司的市值為 1.4405 億美元，市盈率為-0.68，貝塔係數為 1.07。該公司的 50 日移動平均價格為 7.33 美元，200 日移動平均價格為 10.77 美元。Adverum 生物科技的 12 個月最低價為 6.38 美元，最高價為 29.70 美元。</p>
</div><p>Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.58. As a group, research analysts predict that Adverum Biotechnologies will post -5.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Adverum 生物科技（NASDAQ:ADVM - 獲取免費報告）於 8 月 12 日星期一發布了季度財報。這家生物技術公司報告稱，該季度每股虧損為（0.89）美元，超過了每股（1.47）美元的共識預期，增加了 0.58 美元。研究分析師預測，Adverum 生物科技今年將實現-5.5 美元的每股收益。</p>
</div><h2>Insider Activity at Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>Adverum 生物科技內部交易活動</h2>
</div><p>In other Adverum Biotechnologies news, major shareholder Braden Michael Leonard bought 85,800 shares of the company's stock in a transaction on Tuesday, July 30th. The shares were bought at an average price of $7.15 per share, for a total transaction of $613,470.00. Following the transaction, the insider now owns 2,268,064 shares of the company's stock, valued at approximately $16,216,657.60. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. 4.20% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Adverum 生物科技的消息中，主要股東 Braden Michael Leonard 於 7 月 30 日星期二以每股 7.15 美元的平均價格購買了公司的 85,800 股股票。交易金額為 613,470.00 美元。交易後，該內部人士現在持有公司股票的 2,268,064 股，價值約 16,216,657.60 美元。該交易已在提交給證券交易委員會的文件中披露，可在此超鏈接中找到。公司股份的 4.20% 歸內部人士所有。</p>
</div><h2>Institutional Investors Weigh In On Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>機構投資者對 Adverum 生物科技的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of ADVM. Picton Mahoney Asset Management acquired a new stake in shares of Adverum Biotechnologies in the 1st quarter valued at about $1,755,000. Assenagon Asset Management S.A. raised its stake in Adverum Biotechnologies by 72.3% during the second quarter. Assenagon Asset Management S.A. now owns 617,910 shares of the biotechnology company's stock valued at $4,239,000 after buying an additional 259,191 shares in the last quarter. Avoro Capital Advisors LLC bought a new position in Adverum Biotechnologies during the 1st quarter worth approximately $5,892,000. Squarepoint Ops LLC grew its position in shares of Adverum Biotechnologies by 301.1% in the 2nd quarter. Squarepoint Ops LLC now owns 108,978 shares of the biotechnology company's stock worth $748,000 after acquiring an additional 81,808 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Adverum Biotechnologies by 52.9% in the 2nd quarter. Marshall Wace LLP now owns 204,619 shares of the biotechnology company's stock valued at $1,404,000 after acquiring an additional 70,768 shares during the last quarter. 48.17% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買賣了 ADVM 的股票。Picton Mahoney Asset Management 在第一季度收購了 Adverum 生物科技的股份，價值約 1,755,000 美元。Assenagon Asset Management S.A.在第二季度增加了對 Adverum 生物科技的持股，持股比例增加了 72.3%，現在擁有 617,910 股該生物技術公司的股票，價值 4,239,000 美元，較上一季度增加了 259,191 股。Avoro Capital Advisors LLC 在第一季度購買了 Adverum 生物科技的新頭寸，價值約 5,892,000 美元。Squarepoint Ops LLC 在第二季度將其對 Adverum 生物科技的持倉增加了 301.1%。Squarepoint Ops LLC 現在擁有 108,978 股該生物技術公司的股票，價值 748,000 美元，較上一季度增加了 81,808 股。最後，Marshall Wace LLP 在第二季度增加了對 Adverum 生物科技的持股比例 52.9%。Marshall Wace LLP 現在擁有 204,619 股該生物技術公司的股票，價值 1,404,000 美元，較上一季度增加了 70,768 股。48.17% 的股份目前由對沖基金和其他機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>ADVM has been the subject of a number of research analyst reports. StockNews.com upgraded shares of Adverum Biotechnologies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, August 15th. HC Wainwright reiterated a &#34;buy&#34; rating and set a $30.00 price target on shares of Adverum Biotechnologies in a research report on Tuesday, August 13th. Royal Bank of Canada decreased their price target on Adverum Biotechnologies from $15.00 to $12.00 and set a &#34;sector perform&#34; rating on the stock in a research note on Tuesday, August 13th. Oppenheimer assumed coverage on Adverum Biotechnologies in a research note on Tuesday, June 25th. They issued an &#34;outperform&#34; rating and a $25.00 price objective for the company. Finally, Truist Financial reduced their price objective on Adverum Biotechnologies from $60.00 to $40.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $28.17.</p>
<div class="lb-trans"><p>ADVM 已成為多家研究分析師報告的主題。StockNews.com 在 8 月 15 日的報告中將 Adverum 生物科技的股票評級從 “賣出” 調升至 “持有”。HC Wainwright 重申了對 Adverum 生物科技的 “買入” 評級，並設定了 30.00 美元的價格目標。皇家銀行降低了對 Adverum 生物科技的價格目標，從 15.00 美元降至 12.00 美元，並在一份研究報告中將其股票評級定為 “行業表現”。Oppenheimer 在 6 月 25 日的研究報告中對 Adverum 生物科技進行了覆蓋。他們給出了 “表現優異” 的評級，併為該公司設定了 25.00 美元的價格目標。最後，Truist Financial 將 Adverum 生物科技的價格目標從 60.00 美元降至 40.00 美元，併為該公司設定了 “買入” 評級。兩家分析師給予該股票持有評級，五家給予買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “中等買入”，共識目標價為 28.17 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Adverum Biotechnologies</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Adverum 生物科技的最新股票報告</strong></p>
</div><h2>About Adverum Biotechnologies (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Adverum 生物科技（獲取免費報告）</h2>
</div><p>Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.</p>
<div class="lb-trans"><p>Adverum 生物科技公司是一家臨牀階段公司，開發基因療法產品候選藥物以治療眼部疾病。其主要產品候選藥物是 ixoberogene soroparvovec（ADVM-022），這是一種單次眼內注射基因療法候選藥物，用於治療患有濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的患者，目前正在進行 2 期臨牀試驗。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Adverum Biotechnologies</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes</li>
<li>Business Services Stocks Investing</li>
<li>Five Below Stock Faces Challenges Despite Strong Revenue Growth</li>
</ul>
<div class="lb-trans"><h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五支股票勝過 Adverum 生物科技</li>
<li>公用事業股票解釋 - 如何以及為什麼投資公用事業</li>
<li>太陽能股票之戰：大全或晶科能源，哪個是你的下一個大贏家？</li>
<li>投資的不同類型股票</li>
<li>這些中國股票值得購買嗎？邁克爾·伯裏的首選股票説是</li>
<li>商業服務股票投資</li>
<li>儘管收入增長強勁，Five Below 股票面臨挑戰</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Exposed: 3 CENT Crypto to Explode September 23rd? (From True Market Insiders)(Ad)</p>
<div class="lb-trans"><p>→ 揭示：9 月 23 日將爆發 3 美分加密貨幣？（來自 True Market Insiders）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzYz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9363&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Adverum Biotechnologies right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買 Adverum 生物科技的股票？</h2>
</div><p>Before you consider Adverum Biotechnologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Adverum 生物科技之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adverum Biotechnologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了頂級分析師悄悄告訴客户現在應該購買的五隻股票，然後等待整個市場的關注... 而 Adverum Biotechnologies 並不在這份名單上。</p>
</div><p>While Adverum Biotechnologies currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Adverum Biotechnologies 目前在分析師中有一個 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Adverum 生物科技公司（納斯達克代碼：ADVM）空頭頭寸顯著增加